CN1310918C - 作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶 - Google Patents

作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶 Download PDF

Info

Publication number
CN1310918C
CN1310918C CNB038244489A CN03824448A CN1310918C CN 1310918 C CN1310918 C CN 1310918C CN B038244489 A CNB038244489 A CN B038244489A CN 03824448 A CN03824448 A CN 03824448A CN 1310918 C CN1310918 C CN 1310918C
Authority
CN
China
Prior art keywords
compound
alkyl
aryl
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038244489A
Other languages
English (en)
Chinese (zh)
Other versions
CN1738821A (zh
Inventor
T·J·古兹
K·帕鲁奇
M·P·德怀尔
R·J·多尔
V·M·吉里亚瓦拉布汉
L·W·迪拉德
V·D·特兰
Z·M·何
R·A·詹姆斯
朴涵宋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Pharmacopeia LLC
Original Assignee
Pharmacopeia Drug Discovery Inc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Drug Discovery Inc, Schering Corp filed Critical Pharmacopeia Drug Discovery Inc
Publication of CN1738821A publication Critical patent/CN1738821A/zh
Application granted granted Critical
Publication of CN1310918C publication Critical patent/CN1310918C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038244489A 2002-09-04 2003-09-03 作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶 Expired - Fee Related CN1310918C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40803002P 2002-09-04 2002-09-04
US60/408,030 2002-09-04

Publications (2)

Publication Number Publication Date
CN1738821A CN1738821A (zh) 2006-02-22
CN1310918C true CN1310918C (zh) 2007-04-18

Family

ID=31978549

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038244489A Expired - Fee Related CN1310918C (zh) 2002-09-04 2003-09-03 作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶

Country Status (17)

Country Link
US (2) US7078525B2 (https=)
EP (1) EP1534709B1 (https=)
JP (2) JP2006501260A (https=)
KR (1) KR20050058507A (https=)
CN (1) CN1310918C (https=)
AR (1) AR041134A1 (https=)
AT (1) ATE364608T1 (https=)
CA (1) CA2497444C (https=)
DE (1) DE60314427T2 (https=)
ES (1) ES2285164T3 (https=)
MX (1) MXPA05002573A (https=)
MY (1) MY139336A (https=)
NZ (1) NZ539162A (https=)
PE (1) PE20041076A1 (https=)
TW (1) TW200413377A (https=)
WO (1) WO2004022559A1 (https=)
ZA (1) ZA200501851B (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA05002571A (es) * 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
ES2285164T3 (es) * 2002-09-04 2007-11-16 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE60313872T2 (de) 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196092B2 (en) * 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7557110B2 (en) 2003-02-28 2009-07-07 Teijin Pharma Limited Pyrazolo[1,5-A] pyrimidine derivatives
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
EP1644003A1 (en) * 2003-06-04 2006-04-12 Vernalis (Cambridge) Limited Triazolo ´1,5-a!pyrimidines and their use in medicine
AU2004272437A1 (en) * 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
JP2009507843A (ja) 2005-09-09 2009-02-26 シェーリング コーポレイション アザ縮合サイクリン依存性キナーゼ阻害剤
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
CN101321759A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
GB0704652D0 (en) * 2007-03-09 2007-04-18 Syngenta Participations Ag Novel herbicides
CA2689667A1 (en) * 2007-06-07 2008-12-18 Schering Corporation Synthesis of substituted-3-aminopyrazoles
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20100190747A1 (en) 2009-01-27 2010-07-29 Hideo Suzuki Fused ring compound and use thereof
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
US10953012B2 (en) 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
CN104136399B (zh) 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
US10392389B2 (en) 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
CA2889919C (en) 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
KR20150130491A (ko) 2013-03-13 2015-11-23 제넨테크, 인크. 피라졸로 화합물 및 그것의 용도
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
CN105492429A (zh) 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
MX373102B (es) 2014-06-05 2020-04-17 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
JP2018520201A (ja) * 2015-07-23 2018-07-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｇｆベーター受容体アンタゴニスト
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
MX2018006250A (es) 2015-11-18 2018-09-05 Genzyme Corp Biomarcador de enfermedad poliquistica renal y usos del mismo.
CN108017641B (zh) * 2016-11-02 2021-01-05 深圳铂立健医药有限公司 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1474818A (zh) * 2000-11-17 2004-02-11 石原产业株式会社 含有稠合杂环化合物或其盐的糖尿病预防或治疗药

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6157587A (ja) * 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
AU651986B2 (en) * 1991-04-22 1994-08-11 Otsuka Pharmaceutical Factory, Inc. Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
WO1995035298A1 (en) * 1994-06-21 1995-12-28 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
FR2805160B1 (fr) 2000-02-23 2002-04-05 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture
US6282096B1 (en) * 2000-04-28 2001-08-28 Siliconware Precision Industries Co., Ltd. Integration of heat conducting apparatus and chip carrier in IC package
FR2817469B1 (fr) 2000-12-04 2003-04-18 Oreal Composition de coloration, procede d'obtention et utilisation pour la coloration de fibres keratiniques
EP1345941A1 (fr) 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
JP4733794B2 (ja) * 2000-12-26 2011-07-27 共栄電工株式会社 部材内面の表面処理方法および装置
US6919815B2 (en) * 2002-01-24 2005-07-19 Emerson Electric Co. Appliance control communication methods and apparatus
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
MXPA05002571A (es) * 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
ES2285164T3 (es) * 2002-09-04 2007-11-16 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1474818A (zh) * 2000-11-17 2004-02-11 石原产业株式会社 含有稠合杂环化合物或其盐的糖尿病预防或治疗药

Also Published As

Publication number Publication date
US7078525B2 (en) 2006-07-18
CN1738821A (zh) 2006-02-22
ZA200501851B (en) 2005-09-08
CA2497444A1 (en) 2004-03-18
HK1071570A1 (en) 2005-07-22
ES2285164T3 (es) 2007-11-16
MY139336A (en) 2009-09-30
NZ539162A (en) 2006-07-28
AU2003268357A1 (en) 2004-03-29
MXPA05002573A (es) 2005-09-08
EP1534709A1 (en) 2005-06-01
ATE364608T1 (de) 2007-07-15
DE60314427T2 (de) 2008-06-12
JP2010132704A (ja) 2010-06-17
KR20050058507A (ko) 2005-06-16
EP1534709B1 (en) 2007-06-13
JP2006501260A (ja) 2006-01-12
US7470695B2 (en) 2008-12-30
DE60314427D1 (de) 2007-07-26
AR041134A1 (es) 2005-05-04
CA2497444C (en) 2010-11-30
TW200413377A (en) 2004-08-01
PE20041076A1 (es) 2005-01-22
WO2004022559A1 (en) 2004-03-18
US20040102451A1 (en) 2004-05-27
US20060235025A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
CN1310918C (zh) 作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶
CN1701073A (zh) 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5－a]嘧啶
CN1701074A (zh) 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶
CN1694886A (zh) 作为周期素依赖性激酶抑制剂的咪唑并吡嗪
CN1922185A (zh) 作为激酶抑制剂的吡唑并三嗪类化合物
CN1703414A (zh) 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶
CN1694705A (zh) 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶
CN1138778C (zh) 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
CN1289501C (zh) 三环稠合杂环化合物、其制备方法以及包含该化合物的药物
CN1946725A (zh) 用作细胞周期蛋白依赖激酶抑制剂的新型吡唑并嘧啶
ES2574782T3 (es) Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclina
CN1694706A (zh) 用作依赖细胞周期蛋白的激酶抑制剂的新的咪唑并吡嗪
CN1681816A (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并吡啶
JP2006501260A5 (https=)
CN1735614A (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
CN101589045A (zh) 作为蛋白质激酶抑制剂的咪唑并吡嗪
CN1278819A (zh) 作为促肾上腺皮质素释放激素拮抗剂、可用于治疗cns障碍和紧张相关性疾病的杂环基取代的环稠合吡啶和嘧啶
JP2006502184A5 (https=)
CN1183099A (zh) 抑制蛋白质酪氨酸激酶介导的细胞增殖的吡啶并[2,3－d]嘧啶
EP1931641B1 (en) NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHI
CN101541804A (zh) 作为细胞周期素依赖性激酶抑制剂的吡唑并嘧啶
CN101316848A (zh) 用作细胞周期蛋白依赖性激酶抑制剂的新的吡唑并嘧啶化合物
CN1812986A (zh) 呋咱并苯并咪唑类化合物
EP3294297B1 (en) Pyrimidinone amide compounds as pde2 inhibitors
CN1225637A (zh) 吡咯并三嗪和嘧啶化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SCHERING CORP.; PHARMACOPEIA INC.

Free format text: FORMER NAME OR ADDRESS: SCHERING CORP.; PHARMECPIA DRUG R + D CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: New jersey, USA

Co-patentee after: PHARMACOPEIA, Inc.

Patentee after: SCHERING Corp.

Address before: New jersey, USA

Co-patentee before: PHARMACOPEIA DRUG DISCOVERY, Inc.

Patentee before: SCHERING Corp.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070418

Termination date: 20110903